U.S. Markets closed
  • S&P Futures

    4,593.75
    +27.50 (+0.60%)
     
  • Dow Futures

    34,576.00
    +119.00 (+0.35%)
     
  • Nasdaq Futures

    16,273.75
    +123.25 (+0.76%)
     
  • Russell 2000 Futures

    2,221.90
    +24.60 (+1.12%)
     
  • Gold

    1,772.30
    -1.30 (-0.07%)
     
  • Silver

    22.61
    -0.15 (-0.68%)
     
  • EUR/USD

    1.1322
    -0.0017 (-0.1472%)
     
  • 10-Yr Bond

    1.4430
    -0.1610 (-10.04%)
     
  • Vix

    27.19
    +10.08 (+58.91%)
     
  • GBP/USD

    1.3297
    -0.0004 (-0.0319%)
     
  • USD/JPY

    113.4400
    +0.2600 (+0.2297%)
     
  • BTC-USD

    57,043.60
    -389.29 (-0.68%)
     
  • CMC Crypto 200

    1,466.12
    -1.81 (-0.12%)
     
  • FTSE 100

    7,059.45
    -231.75 (-3.18%)
     
  • Nikkei 225

    28,012.34
    +190.58 (+0.69%)
     

3 Biotech Stocks That Are Ridiculously Overpriced

·6 min read
3 Biotech Stocks That Are Ridiculously Overpriced
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. Here's why they picked Cassava Sciences (NASDAQ: SAVA), Ocugen (NASDAQ: OCGN), and Moderna (NASDAQ: MRNA). Prosper Junior Bakiny (Cassava Sciences): Investors have been flocking to this clinical-stage biotech all year long, pushing its share price up by well over 600%.